Marja-Riitta Taskinen Selected Research

Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial)

1/2016	USF1 deficiency activates brown adipose tissue and improves cardiometabolic health.
1/2016	The Contribution of GWAS Loci in Familial Dyslipidemias.
11/2014	Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia.
1/2010	A nonsynonymous SNP within PCDH15 is associated with lipid traits in familial combined hyperlipidemia.
10/2009	Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias.
8/2009	OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism.
7/2006	Common hepatic nuclear factor-4alpha variants are associated with high serum lipid levels and the metabolic syndrome.
9/2005	USF1 and dyslipidemias: converging evidence for a functional intronic variant.
10/2004	Locus for quantitative HDL-cholesterol on chromosome 10q in Finnish families with dyslipidemia.
8/2004	Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marja-Riitta Taskinen Research Topics

Disease

50	Type 2 Diabetes Mellitus (MODY) 01/2021 - 03/2002
29	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 05/2002
29	Insulin Resistance 01/2021 - 02/2003
26	Dyslipidemias (Dyslipidemia) 01/2021 - 05/2002
24	Atherosclerosis 01/2022 - 01/2002
17	Hypertriglyceridemia 01/2022 - 11/2002
17	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 01/2016 - 01/2002
16	Coronary Disease (Coronary Heart Disease) 01/2016 - 05/2002
14	Coronary Artery Disease (Coronary Atherosclerosis) 01/2019 - 03/2002
12	Inflammation (Inflammations) 01/2021 - 03/2002
12	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2019 - 08/2005
10	Obesity 01/2021 - 06/2007
10	Hyperlipidemias (Hyperlipidemia) 01/2019 - 11/2002
8	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 11/2002
8	Non-alcoholic Fatty Liver Disease 12/2020 - 02/2008
7	Hypertension (High Blood Pressure) 11/2011 - 01/2006
6	Abdominal Obesity 01/2017 - 06/2009
4	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 08/2005
4	Myocardial Infarction 01/2022 - 11/2004
4	Body Weight (Weight, Body) 12/2020 - 04/2005
4	Hyperglycemia 08/2014 - 11/2002
3	Overweight 05/2022 - 06/2009
3	Albuminuria 01/2022 - 02/2006
3	Fatty Liver 01/2022 - 03/2011
3	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020 - 09/2017
3	Vascular Diseases (Vascular Disease) 01/2009 - 05/2002
2	Stroke (Strokes) 01/2022 - 05/2002
2	Diabetes Complications 01/2021 - 01/2020
2	Mitochondrial Myopathies (Mitochondrial Myopathy) 07/2020 - 01/2020
2	Genetic Risk Score 01/2020 - 09/2017
2	Hypercholesterolemia 01/2020 - 09/2014
2	Xanthomatosis (Xanthoma) 08/2014 - 12/2013
2	Pancreatitis 08/2014 - 11/2009
2	Diabetes Mellitus 06/2013 - 08/2010
2	Hypoglycemia (Reactive Hypoglycemia) 05/2013 - 05/2012
2	Pathologic Constriction (Stenosis) 05/2003 - 04/2003

Drug/Important Bio-Agent (IBA)

47	Triglycerides (Triacylglycerol)IBA 05/2022 - 03/2002
42	LipidsIBA 12/2020 - 01/2002
39	Lipoproteins (Lipoprotein)IBA 05/2022 - 04/2002
25	oxidized low density lipoproteinIBA 01/2020 - 01/2002
23	HDL CholesterolIBA 01/2019 - 12/2002
17	CholesterolIBA 01/2022 - 05/2002
16	Glucose (Dextrose)FDA LinkGeneric 05/2022 - 11/2002
15	Fenofibrate (CiL)FDA LinkGeneric 01/2021 - 03/2002
12	LDL CholesterolIBA 01/2020 - 05/2002
10	Apolipoprotein C-IIIIBA 01/2022 - 06/2005
10	ApolipoproteinsIBA 01/2021 - 11/2002
10	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020 - 01/2002
10	Insulin (Novolin)FDA Link 01/2019 - 11/2002
9	Biomarkers (Surrogate Marker)IBA 12/2020 - 10/2002
8	HDL LipoproteinsIBA 04/2015 - 09/2002
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2002
7	IsotopesIBA 01/2021 - 09/2011
6	Apolipoprotein A-I (Apolipoprotein A1)IBA 04/2016 - 06/2007
5	Apolipoproteins B (ApoB)IBA 09/2017 - 01/2009
5	Transcription Factors (Transcription Factor)IBA 01/2016 - 04/2004
5	VLDL LipoproteinsIBA 11/2014 - 06/2005
5	Metformin (Glucophage)FDA LinkGeneric 05/2013 - 05/2009
4	Niacin (Nicotinic Acid)FDA LinkGeneric 07/2020 - 06/2011
4	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 02/2008
4	fibroblast growth factor 21IBA 07/2017 - 03/2012
4	AdiponectinIBA 07/2015 - 04/2005
4	Exenatide (Byetta)FDA Link 09/2011 - 05/2009
4	Gemfibrozil (Lopid)FDA LinkGeneric 04/2004 - 03/2002
3	AlbuminsIBA 01/2022 - 03/2005
3	Liraglutide FDA Link 01/2021 - 01/2019
3	Uric Acid (Urate)IBA 01/2021 - 06/2011
3	PPAR alphaIBA 01/2019 - 03/2002
3	Leucine (L-Leucine)FDA Link 10/2015 - 03/2002
3	Aryldialkylphosphatase (Paraoxonase)IBA 01/2014 - 06/2006
3	EnzymesIBA 01/2014 - 04/2002
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2012 - 04/2010
3	Lipase (Acid Lipase)FDA Link 05/2012 - 10/2009
3	CreatinineIBA 06/2011 - 08/2005
3	Blood Glucose (Blood Sugar)IBA 06/2011 - 05/2002
3	Insulin Glargine (Lantus)FDA Link 09/2010 - 05/2009
3	Pharmaceutical PreparationsIBA 09/2010 - 11/2002
2	LeptinIBA 01/2021 - 04/2005
2	Serine (L-Serine)FDA Link 01/2020 - 01/2017
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2020 - 01/2017
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2019 - 01/2016
2	CytokinesIBA 12/2018 - 04/2015
2	alirocumabIBA 01/2018 - 09/2014
2	Apolipoprotein A-II (Apolipoprotein A2)IBA 04/2016 - 06/2009
2	Messenger RNA (mRNA)IBA 01/2016 - 02/2006
2	Glycerol (Glycerine)FDA LinkGeneric 10/2015 - 11/2014
2	Apolipoprotein B-48IBA 11/2014 - 07/2010
2	Apolipoproteins AIBA 11/2014 - 08/2007
2	Apolipoprotein A-VIBA 11/2014 - 08/2007
2	Ezetimibe (Zetia)FDA Link 09/2014 - 12/2012
2	Adenosine Triphosphate (ATP)IBA 11/2011 - 03/2009
2	HomocysteineIBA 06/2009 - 02/2004
2	Apolipoproteins E (ApoE)IBA 05/2008 - 06/2005
2	Indicators and Reagents (Reagents)IBA 02/2006 - 05/2002
2	Platelet Endothelial Cell Adhesion Molecule-1IBA 11/2004 - 05/2003
1	Peptides (Polypeptides)IBA 05/2022
1	Glucagon-Like Peptides (Enteroglucagon)IBA 05/2022
1	omega-Chloroacetophenone (Mace)IBA 01/2022

Therapy/Procedure

10	Therapeutics 01/2019 - 10/2002
7	Glycemic Control 08/2014 - 11/2002